Clinical trials: Cancer Head &Neck
Prostate Cancer, Melanoma
Safety Study of MGA271 in Refractory Cancer
The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer.
- Conditions
- Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT01391143
- Testing
- MGA271
- Where
- 12 sites in United States
- Volunteers
- 179 people
- Sponsor
- MacroGenics
Carcinoma, Head and Neck Cancer
Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab
Primary: to compare the overall survival defined as the time elapsed between the randomization date and death due to any cause, in both treatment groups.
- Trial name
- NICAP (NCT01345084)
- Testing
- Radiation Therapy, Nimotuzumab, Cisplatin
- Where
- 8 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Esophageal Cancer, Gastric Cancer
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06500052
- Testing
- BL-M17D1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Cancer, Head and Neck Neoplasms
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04634825
- Testing
- Enoblituzumab, Retifanlimab, Tebotelimab
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 62 people
- Sponsor
- MacroGenics
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma, Unknown Primary
Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery
This is a single-arm, single site, multi-surgeon prospective feasibility study for transoral robot assisted surgery (TORS) with the Versius Surgical System.
- Trial name
- NCT06112535
- Testing
- Versius Surgical System
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- CMR Surgical Ltd
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer
- Trial name
- NCT03906331
- Testing
- Selpercatinib
- Where
- 64 sites in United States, Australia and 11 more
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E)
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E)
- Trial name
- NCT02637531
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 219 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma
Validity of Viome's Oral/throat Cancer Test
A total of at least 1,000 participants with suspicion of cancer including at least 107 subjects who will be diagnosed with OSCC or OPSCC will be enrolled from either primary or secondary care centers in the U.S.
- Conditions
- Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
- Trial name
- NCT06174428
- Testing
- Oral/Throat cancer test
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Viome
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer
Dose escalation part:to determine the highest dose of BYL719 administered on a daily basis when given in combination with weekly paclitaxel Dose escalation part: to confirm the safety and tolerability of the BYL719 and paclitaxel…
- Trial name
- NCT02051751
- Testing
- BYL719, Paclitaxel
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Cancer
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled…
- Trial name
- NCT04415853
- Testing
- Lerotinib, Irinotecan/Tegafur
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Oesophageal Cancer, Oesophageal Disease
EndoVE endosCopic Treatment for Oesophageal and Gastric canceR
This project aims to establish the safety and efficacy of treating patients with inoperable oesophageal cancer or gastric cancer, using an endoscopic electroporation system (EndoVE) to facilitate direct chemotherapy tumour…
- Conditions
- Oesophageal Cancer, Oesophageal Disease, Gastric Cancer
- Trial name
- VECTOR (NCT04649372)
- Testing
- EndoVE
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Mirai Medical
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Head and Neck Cancer
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
- Trial name
- IRESSA&H&N (NCT00681967)
- Testing
- Gefitinib
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Neoplasms
p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , with concurrent radiotherapy, or combination with surgery…
- Trial name
- NCT00894153
- Testing
- chemotherapy plus p53, chemotherapy, radiotherapy
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
Gastrointestinal Cancer
Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer
In this study, researchers wanted to learn more about the effect of Aspirin taken as low dose (75 - 300 mg) in preventing stomach, colorectal and esophagus cancer.
- Trial name
- ENgAGE-HK (NCT04081831)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- Hong Kong
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Advanced Solid Tumors
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab.
- Trial name
- NCT03000257
- Testing
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 182 people
- Sponsor
- AbbVie
Cancer of Head and Neck
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.
- Trial name
- NCT01584284
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Genelux Corporation
Head and Neck Squamous Cell Carcinoma
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
CX1106 is a novel inhibitor of thymidylate synthase (TS) developed as a potential antitumor agent by virtue of the rate limiting role of TS in the biosynthesis of thymidine.
- Trial name
- HNSCC (NCT04093115)
- Testing
- CX1106
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.